Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BSGM SEC filings archive on Stock Titan presents the regulatory record of the company formerly known as BioSig Technologies, Inc., which has since rebranded as Streamex Corp. and now trades under the symbol STEX. These documents trace the company’s transition from a medical device technology issuer to a business focused on real-world asset and gold tokenization.
Key filings include multiple Current Reports on Form 8-K detailing material events such as the merger with Streamex Exchange Corporation, the amendment to the certificate of incorporation changing the corporate name to Streamex Corp., and the Nasdaq ticker symbol change from BSGM to STEX. Other 8-K filings describe the secured convertible debenture purchase agreement with an institutional investor, the issuance of an initial tranche of convertible debentures, and related security and registration rights agreements.
The archive also contains a definitive proxy statement on Form DEF 14A for the company’s annual meeting, which outlines proposals including director elections, executive compensation advisory votes, auditor ratification, and amendments to the long-term incentive plan. Additional filings report amendments to the certificate of incorporation to increase authorized shares and to classify the board into staggered terms, as well as a tokenized yield partnership agreement related to precious-metal lease and bond programs.
On Stock Titan’s filings page, investors can review these historical BSGM documents alongside AI-powered summaries that explain the main terms, structures, and implications of each report. The feed updates as new Streamex Corp. (STEX) filings appear in the SEC’s EDGAR system, allowing users to follow the company’s ongoing regulatory disclosures, including future 10-K annual reports, 10-Q quarterly reports, and any Form 4 insider transaction filings associated with the successor entity.
BioSig Technologies amended a secured convertible debenture purchase agreement with YA II PN, Ltd. (Yorkville). The Amendment revises the transaction structure to provide a first secured convertible debenture in the principal amount of $25,000,000 and a second secured convertible debenture in the principal amount of $25,000,000, with additional secured convertible debentures available in an aggregate principal amount of up to $50,000,000 only upon mutual agreement of the parties.
The Amendment also modifies certain purchase, closing and stockholder approval provisions and updates related terms, including setting the conversion floor price at 20% of the Nasdaq Official Closing Price immediately prior to the date of entry into the original Debenture Purchase Agreement. The full Amendment is filed as Exhibit 10.1.
Schedule 13G highlights: Avanico Limited and investor Frank Giustra jointly report beneficial ownership of 17,040,640 exchangeable shares of BioSig Technologies (BSGM), representing 12.13 % of total equity. Only 5.01 % of this block is immediately convertible into common stock; the balance becomes convertible after shareholder approval expected within 60 days.
The stake originates from the 23 May 2025 share-purchase agreement involving BST Sub ULC and Streamex Exchange Corp. Both reporting persons share voting and dispositive power over the full block, with no sole control.
The ownership calculation is based on 140.4 M total shares (31.3 M common + 109.1 M exchangeable). Full conversion would add up to 17 M new common shares, expanding the tradable float by roughly 54 % versus today’s outstanding common stock.
Item 10 certification indicates the shares were acquired for investment, not to influence control of BioSig.